annb0t
Top 20
Bionomics Limited (NASDAQ: BNOX) announced results from its Phase PREVAIL study of BNC210 for the acute treatment of Social Anxiety Disorder (SAD), showing a miss on the primary endpoint. HC Wainwright, while downgrading the stock to Neutral from Buy, discussed the history of BNC210 and the PTSD program previously. The analyst writes that it has received baseline support from models of conditioned fear extinction and clinical effect from enhanced emotional recovery from CCK-induced panic attacks...
>>> Read more: All Focus Shifts To Bionomics' PTSD Study After Anxiety Trial Disappoints
>>> Read more: All Focus Shifts To Bionomics' PTSD Study After Anxiety Trial Disappoints
